• BioVie posted a net loss of USD 5.3 million for the quarter ended March 31, 2026, widening from USD 2.8 million a year earlier.
• Operating expenses climbed to USD 5.4 million from USD 3 million, driven by R&D spending of USD 3.2 million and general and administrative costs of USD 2.2 million.
• R&D outlays rose as Sunrise PD Phase 2 costs increased to USD 2.06 million, while Long COVID Phase 2 costs were USD 2.65 million offset by USD 3.06 million of reimbursements.
• Cash and cash equivalents were USD 13.1 million at March 31, 2026, with working capital of USD 15.2 million.
• BioVie reiterated expectations to report topline results in mid-year 2026 from its Phase 2b bezisterim trial in newly diagnosed Parkinson’s disease patients, with 60 patients enrolled in December 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioVie Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001520138-26-000154), on May 11, 2026, and is solely responsible for the information contained therein.